Last 7 days
-0.2%
Last 30 days
1.0%
Last 90 days
-1.2%
Trailing 12 Months
4.1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MDT | 104.6B | 30.8B | -8.05% | -24.94% | 25.73 | 3.4 | -3.19% | -17.38% |
SYK | 104.4B | 18.4B | 5.66% | 8.69% | 44.29 | 5.66 | 7.84% | 18.25% |
ISRG | 85.7B | 6.2B | 4.83% | -11.02% | 64.81 | 13.77 | 8.97% | -22.43% |
BDX | 67.1B | 19.0B | -1.08% | -7.00% | 41.67 | 3.53 | -0.43% | -8.78% |
EW | 48.6B | 5.4B | 5.76% | -25.47% | 31.94 | 9.03 | 2.86% | 1.25% |
MID-CAP | ||||||||
SWAV | 7.2T | 489.7M | 12.31% | 16.47% | 82.2K | 16.8K | 106.51% | 2464.23% |
PEN | 10.6B | 847.1M | 7.52% | 34.43% | -5.3K | 12.49 | 13.32% | -137.89% |
GMED | 5.2B | 1.0B | -10.91% | -22.50% | 30.47 | 5.13 | 6.76% | 24.45% |
IRTC | 3.6B | 410.9M | 10.60% | -14.17% | -31.18 | 8.81 | 27.29% | -14.60% |
TNDM | 2.7B | 801.2M | 8.08% | -61.27% | -28.75 | 3.39 | 14.00% | -707.69% |
SMALL-CAP | ||||||||
SILK | 1.5B | 138.6M | -22.14% | 5.45% | -28.06 | 11.13 | 36.62% | -10.44% |
AVNS | 1.3B | 820.0M | -2.41% | -12.43% | 26.08 | 1.61 | 10.13% | 701.59% |
BLFS | 942.5M | 154.8M | 4.20% | -0.45% | -9.06 | 6.09 | 60.29% | -2309.58% |
CSII | 828.8M | 239.8M | 0.30% | -2.08% | -21.89 | 3.46 | -4.74% | -31.15% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 0.7% | 6,940 | 6,892 | 6,908 | 6,889 | 6,827 |
S&GA Expenses | -2.8% | 2,762 | 2,840 | 2,869 | 2,871 | 2,843 |
EBITDA | 0.9% | 1,165 | 1,155 | 1,050 | 1,167 | - |
EBITDA Margin | 0.2% | 0.17* | 0.17* | 0.15* | 0.15* | - |
Earnings Before Taxes | 2.3% | 404 | 394 | 408 | 386 | 499 |
EBT Margin | 1.6% | 0.06* | 0.06* | 0.04* | 0.04* | - |
Interest Expenses | 3.6% | -164 | -171 | -181 | -197 | -208 |
Net Income | -16.7% | 231 | 278 | 230 | 218 | 402 |
Net Income Margin | -17.3% | 0.03* | 0.04* | 0.03* | 0.03* | - |
Free Cahsflow | -8.4% | 1,168 | 1,276 | 1,294 | 1,416 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -1.3% | 21,066 | 21,333 | 21,453 | 21,618 | 23,456 |
Current Assets | -2.4% | 4,427 | 4,534 | 4,463 | 4,517 | 4,885 |
Cash Equivalents | -31.1% | 376 | 545 | 386 | 436 | 378 |
Inventory | 0.9% | 2,147 | 2,129 | 2,123 | 2,132 | 2,148 |
Net PPE | 3.9% | 1,873 | 1,802 | 1,797 | 1,826 | 1,837 |
Goodwill | -2.5% | 8,580 | 8,799 | 8,869 | 8,896 | 8,919 |
Liabilities | -0.5% | 9,039 | 9,082 | 9,328 | 9,596 | 10,790 |
Current Liabilities | 2.7% | 2,358 | 2,296 | 2,464 | 2,674 | 3,468 |
Long Term Debt | -5.3% | 5,263 | 5,560 | 5,995 | 7,216 | - |
LT Debt, Current | -17.4% | 544 | 659 | 852 | 1,015 | 1,605 |
LT Debt, Non Current | 1.9% | 5,152 | 5,055 | 5,172 | 5,286 | 5,464 |
Shareholder's Equity | -1.8% | 12,020 | 12,245 | 12,125 | 12,021 | 12,661 |
Retained Earnings | -1.9% | 9,559 | 9,740 | 9,607 | 9,503 | 10,292 |
Additional Paid-In Capital | 0.4% | 9,504 | 9,464 | 9,419 | 9,386 | 9,315 |
Accumulated Depreciation | 0.1% | 4,543 | 4,540 | 4,442 | 4,301 | - |
Shares Outstanding | 0.1% | 210 | 210 | 209 | - | - |
Minority Interest | 4.7% | 7.00 | 6.00 | 6.00 | 6.00 | 6.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -6.4% | 1,356 | 1,450 | 1,423 | 1,497 | 1,404 |
Share Based Compensation | 12.8% | 105 | 93.00 | 84.00 | 79.00 | 76.00 |
Cashflow From Investing | 2.2% | -522 | -533 | -560 | -416 | -443 |
Cashflow From Financing | 30.6% | -775 | -1,118 | -1,350 | -1,232 | -1,306 |
Dividend Payments | 0.1% | 201 | 201 | 201 | 201 | 200 |
Buy Backs | - | 126 | - | - | - | - |
72.3%
34.6%
18.5%
Y-axis is the maximum loss one would have experienced if Zimmer Biomet Holdings was unfortunately bought at previous high price.
6.7%
3.8%
4.3%
17.4%
FIve years rolling returns for Zimmer Biomet Holdings.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 1.29 | 86,573 | 452,573 | 0.01% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 657 | 158,479,000 | 177,730,000 | 0.19% |
2023-03-08 | Capital Asset Advisory Services LLC | reduced | -5.93 | 50,190 | 392,190 | 0.03% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | reduced | -4.8 | 61,297 | 442,297 | 0.03% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -31.63 | -229,000 | 1,146,000 | 0.01% |
2023-03-03 | TIAA, FSB | added | 10.48 | 352,585 | 1,368,580 | -% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 50,873 | 50,873 | -% |
2023-03-01 | WHITENER CAPITAL MANAGEMENT, INC. | new | - | 247,988 | 247,988 | 0.11% |
2023-03-01 | Lakewood Asset Management LLC | new | - | 355,000 | 355,000 | 0.29% |
2023-03-01 | Meixler Investment Management, Ltd. | reduced | -1.45 | 67,980 | 406,980 | 0.41% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | price t rowe associates inc /md/ | 5.3% | 11,200,109 | SC 13G | |
Feb 09, 2023 | vanguard group inc | 11.46% | 24,055,739 | SC 13G/A | |
Jan 30, 2023 | blackrock inc. | 10.4% | 21,803,709 | SC 13G/A | |
Jan 24, 2023 | blackrock inc. | 10.4% | 21,803,709 | SC 13G/A | |
Apr 08, 2022 | vanguard group inc | 11.04% | 23,102,761 | SC 13G/A | |
Jan 28, 2022 | jpmorgan chase & co | 5.4% | 11,340,168 | SC 13G | |
Jan 28, 2022 | blackrock inc. | 10.4% | 21,793,439 | SC 13G/A | |
Apr 12, 2021 | blackrock inc. | 10.0% | 20,926,542 | SC 13G/A | |
Feb 11, 2021 | massachusetts financial services co /ma/ | 4.8% | 10,001,947 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 7.58% | 15,703,785 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 31.70 -74.68% | 35.85 -71.36% | 41.30 -67.01% | 54.91 -56.14% | 64.23 -48.69% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 21, 2023 | 4 | Insider Trading | |
Mar 17, 2023 | 144 | Notice of Insider Sale Intent | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-17 | Phipps Chad F | sold | -2,869,110 | 124 | -23,045 | sr. vp/gen counsel/secretary |
2023-03-17 | Phipps Chad F | acquired | 1,635,500 | 70.97 | 23,045 | sr. vp/gen counsel/secretary |
2023-03-02 | Winkler Lori | sold (taxes) | -6,839 | 122 | -56.00 | svp and chro |
2023-03-02 | Winkler Lori | acquired | - | - | 187 | svp and chro |
2023-02-21 | Tornos Ivan | sold (taxes) | -203,060 | 124 | -1,628 | chief operating officer |
2023-02-21 | Hanson Bryan C | acquired | - | - | 15,132 | president and ceo |
2023-02-21 | Hanson Bryan C | sold (taxes) | -592,717 | 124 | -4,752 | president and ceo |
2023-02-21 | Upadhyay Suketu | acquired | - | - | 3,860 | exec. vp, cfo |
2023-02-21 | Ellingson Rachel | acquired | - | - | 1,046 | svp & chief strategy officer |
2023-02-21 | Yi Sang | acquired | - | - | 2,423 | president, asia pacific |
Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Net Sales | $ 6,939.9 | $ 6,827.3 | $ 6,127.5 |
Type of Revenue [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
Cost of products sold, excluding intangible asset amortization | $ 2,019.5 | $ 1,960.4 | $ 1,824.3 |
Type of Cost, Good or Service [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
Intangible asset amortization | $ 526.8 | $ 529.5 | $ 512.1 |
Research and development | 406.0 | 435.8 | 322.8 |
Selling, general and administrative | 2,761.7 | 2,843.4 | 2,712.7 |
Goodwill and intangible asset impairment | 292.8 | 16.3 | 503.0 |
Restructuring and other cost reduction initiatives | 191.6 | 125.7 | 107.2 |
Quality remediation | 33.8 | 52.8 | 50.9 |
Acquisition, integration, divestiture and related | 11.4 | 3.1 | 11.4 |
Operating expenses | 6,243.6 | 5,967.0 | 6,044.4 |
Operating Profit | 696.3 | 860.3 | 83.1 |
Other (expense) income, net | (128.0) | 12.2 | 23.8 |
Interest expense, net | (164.8) | (208.4) | (212.1) |
Loss on early extinguishment of debt | (165.1) | ||
Earnings (Loss) before income taxes | 403.5 | 499.0 | (105.2) |
Provision (benefit) for income taxes from continuing operations | 112.3 | 53.5 | (96.0) |
Net Earnings (Loss) from Continuing Operations | 291.2 | 445.5 | (9.2) |
Less: Net earnings attributable to noncontrolling interest | 1.0 | 0.5 | 1.5 |
Net Earnings (Loss) from Continuing Operations of Zimmer Biomet Holdings, Inc. | 290.2 | 445.0 | (10.7) |
Loss from Discontinued Operations, Net of Tax | (58.8) | (43.4) | (128.2) |
Net Earnings (Loss) of Zimmer Biomet Holdings, Inc. | $ 231.4 | $ 401.6 | $ (138.9) |
Basic Earnings (Loss) Per Common Share | |||
Earnings (Loss) from Continuing Operations | $ 1.38 | $ 2.14 | $ (0.05) |
Loss from Discontinued Operations | (0.28) | (0.21) | (0.62) |
Basic Earnings (Loss) Per Common Share | 1.10 | 1.93 | (0.67) |
Diluted Earnings (Loss) Per Common Share | |||
Earnings (Loss) from Continuing Operations | 1.38 | 2.12 | (0.05) |
Loss from Discontinued Operations | (0.28) | (0.21) | (0.62) |
Diluted Earnings (Loss) Per Common Share | $ 1.10 | $ 1.91 | $ (0.67) |
Weighted Average Common Shares Outstanding | |||
Basic | 209.6 | 208.6 | 207.0 |
Diluted | 210.3 | 210.4 | 207.0 |
Consolidated Balance Sheets - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 375.7 | $ 378.1 |
Accounts receivable, less allowance for credit losses | 1,381.5 | 1,259.6 |
Inventories | 2,147.2 | 2,148.0 |
Prepaid taxes | 198.4 | 326.7 |
Prepaid expenses and other current assets | 324.5 | 271.0 |
Current assets of discontinued operations | 501.6 | |
Total Current Assets | 4,427.3 | 4,885.0 |
Property, plant and equipment, net | 1,872.5 | 1,836.6 |
Goodwill | 8,580.2 | 8,919.4 |
Intangible assets, net | 5,063.8 | 5,533.6 |
Other assets | 1,122.2 | 1,005.0 |
Noncurrent assets of discontinued operations | 1,276.8 | |
Total Assets | 21,066.0 | 23,456.4 |
Current Liabilities: | ||
Accounts payable | 354.1 | 306.5 |
Income taxes payable | 38.5 | 62.0 |
Other current liabilities | 1,421.3 | 1,317.1 |
Current portion of long-term debt | 544.3 | 1,605.1 |
Current liabilities of discontinued operations | 177.2 | |
Total Current Liabilities | 2,358.2 | 3,467.9 |
Deferred income taxes, net | 474.8 | 558.5 |
Long-term income tax payable | 421.2 | 583.0 |
Other long-term liabilities | 632.6 | 548.5 |
Long-term debt | 5,152.2 | 5,463.7 |
Noncurrent liabilities of discontinued operations | 168.4 | |
Total Liabilities | 9,039.0 | 10,790.0 |
Commitments and Contingencies (Note 21) | ||
Stockholders' Equity: | ||
Common stock, $0.01 par value, one billion shares authorized,313.8 million (312.8 million in 2021) issued | 3.1 | 3.1 |
Paid-in capital | 9,504.4 | 9,314.8 |
Retained earnings | 9,559.3 | 10,292.2 |
Accumulated other comprehensive loss | (179.3) | (231.6) |
Treasury stock, 104.8 million shares (103.8 million shares in 2021) | (6,867.2) | (6,717.8) |
Total Zimmer Biomet Holdings, Inc. stockholders' equity | 12,020.3 | 12,660.7 |
Noncontrolling interest | 6.7 | 5.7 |
Total Stockholders' Equity | 12,027.0 | 12,666.4 |
Total Liabilities and Stockholders' Equity | $ 21,066.0 | $ 23,456.4 |